# Altimmune, Inc. Common Stock (ALT)

> Altimmune, Inc. Common Stock (ALT) trades at $1.33 (-5.67%) as of 7:55:14 PM EST on Nov 20, 2026, -38.71% over the past month. Market cap is $258.8M, with 12.2 days to cover in short interest.

Canonical: https://massive.com/quote/alt
Data as of: 2026-11-21T00:55:14.031Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.33** -0.08 (-5.67%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$1.36** +0.03 (+2.26%)
As of 7:55:14 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Altimmune, Inc. Common Stock (ALT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -5.67% |
| 1W | -19.15% |
| 1M | -38.71% |
| YTD | -63.16% |
| 1Y | -73.92% |
| 52-wk range | $1.32 – $6.44 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for ALT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.32 – $1.46 |
| Open | $1.37 |
| Prev close | $1.41 |
| Volume | 4.06M |
| Market cap | $258.8M |
| Shares out | 194.59M |

## Valuation and profitability ratios

Valuation and profitability ratios for Altimmune, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 9954.00 |
| P/B | 0.58 |
| P/FCF | — |
| ROE | -23.6% |
| ROA | -21.1% |
| Debt/Equity | 0.08 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Altimmune, Inc. Common Stock (ALT) insider trading](https://massive.com/quote/alt/insider-trading.md): open-market Form 4 buys and sells by Altimmune, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Altimmune, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Altimmune, Inc. issued a press release announcing the Company's financial results for its third quarter ended September 30, 2026.”
- Oct 29, 2026 · Credit facility
  “As a result of occurrence and satisfaction of the Tranche 3 Milestone, (i) the Amortization Date and interest-only period has been extended to June 1, 2028, and (ii) pursuant to the Minimum Cash covenant set forth in Section 7.19(a)(i) of the Loan Agreement, the Company shall maintain Qualified Cash in an amount greater than or equal to the outstanding principal amount of the Term Loan Advances multiplied by 60%.”
- Oct 27, 2026 · Director appointment
  “On October 23, 2026, the Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors.”
- Sep 29, 2026 · Executive officer appointment
  “On September 24, 2026, the Board of Directors (the "Board") of Altimmune, Inc. (the "Company") appointed Richard Menziuso as the Company's Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.”
- Jul 28, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On July 28, 2026, Altimmune, Inc. (the "Company") issued a press release announcing the positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide 2.4 mg dose, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week (HDD) versus placebo, with positive results across important secondary endpoints, including a two-level reduction in the World Health Organization Risk Drinking Level and zero HDDs, both of which are U.S. Food and Drug Administration (FDA) registrational endpoints, as well as a reduction in phosphatidyl ethanol levels. A generally favorable safety and tolerability profile was observed in the trial.”

## Dividend history and stock splits

Altimmune, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-30 · Sep 14, 2018
- 1-for-10 · May 4, 2017
- 1-for-50 · Jul 25, 2007

## ALT short interest

How heavily ALT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 12.2 |
| Short interest | 42.13M |
| Avg volume | 3.46M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ALT news

The latest news and headlines about Altimmune, Inc. Common Stock (ALT).

- [ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns](https://www.zacks.com/stock/news/3029252/alt-q3-earnings-miss-stock-sinks-on-higher-costs-funding-concerns?cid=CS-ZC-FT-analyst_blog|earnings_article-3029252) · Zacks Investment Research · Nov 13, 2026 · negative sentiment
- [Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026](https://www.globenewswire.com/news-release/2026/11/05/3396650/0/en/altimmune-announces-data-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder-selected-as-late-breaking-oral-presentation-at-aasld-the-liver-meeting-2026.html) · GlobeNewswire Inc. · Nov 5, 2026 · positive sentiment
- [Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options \| DelveInsight](https://www.globenewswire.com/news-release/2026/10/21/3385077/0/en/metabolic-dysfunction-associated-steatohepatitis-clinical-trial-and-competitive-landscape-expands-as-180-companies-target-new-treatment-options-delveinsight.html) · GlobeNewswire Inc. · Oct 20, 2026 · positive sentiment
- [Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?](https://www.zacks.com/stock/news/3001796/can-nvo-s-semaglutide-push-create-growth-beyond-cardiometabolic-care?cid=CS-ZC-FT-analyst_blog|quick_take-3001796) · Zacks Investment Research · Oct 7, 2026 · neutral sentiment
- [Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?](https://www.zacks.com/stock/news/2988561/why-is-altimmune-alt-up-14-2-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2988561) · Zacks Investment Research · Sep 11, 2026 · positive sentiment

## About Altimmune, Inc. Common Stock

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Listed | Oct 6, 2005 |

[Company website](https://www.altimmune.com)

## FAQ

### What is the Altimmune, Inc. Common Stock (ALT) stock price today?

Altimmune, Inc. Common Stock (ALT) is trading at $1.33 (-5.67% on the day) as of 7:55:14 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Altimmune, Inc. Common Stock?

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development…

### What is the short interest in ALT?

As of Oct 30, 2026, ALT has 42.13M shares short and 12.2 days to cover.

### What exchange is ALT listed on?

Altimmune, Inc. Common Stock (ALT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ALT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ALT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Altimmune, Inc. Common Stock (ALT) insider trading](https://massive.com/quote/alt/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
